Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 401-405

  Barbati, Antonella ^a,d   Cosmi, Ermelando V ^b   Sidoni, Angelo ^c   Collini, Patrizia ^b   Porpora, Maria G ^b   Ferri, Ivana ^c   Lüthy, Monika ^c   Lauro, Vincenzo ^a   Bucciarelli, Emilio ^c  

^a University of Penigia   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d POLICLINICO MONTELUCE   (Italy)

Author keywords

Breast cancer; c erbB 2; Immunohistochemistry; p53

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031051158     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Stanford JL, Szklo M, and Brinton LA: Estrogen receptors and breast cancer. Epidemiol Rev 8: 42-59, 1986.
2. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Brit J Cancer 11: 359-77, 1957.
3. Fallenius AG, Aver GU and Carstensen JM: Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 62: 331-41, 1988.
4. Gusterson BA, Machin LG, Gullick WJ et al: c-erbB-2 expression in benign and malignant breast diseases. Br J Cancer 58: 453-7, 1988.
5. Bargmann CI, Hung MC, and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond) 319: 226-30, 1986.
6. Slamon DJ, Godoiphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-12, 1989.
7. Venter DJ, Tsui NL, Kummar S, and Gullick WJ: Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessmant correlated with gene amplification. Lancet 2: 67-72, 1987.
8. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Cells 48: 1238-43, 1988.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 255: 177-82, 1987.
10. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, and Horne CHW: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-90, 1989.
11. Hollstein M, Sidransky D, Volgestein B and Harris CC: p53 mutation in human cancers. Science 253: 49-53, 1991.
12. Cattoretti G, Rilke F, Andreola S, D'amato L, and Delia D: p53 exression in breast Cancer. Int J Cancer 41: 178-83, 1988.
13. Varley JM, Brammer WL, Lane DP et al: Loss of Chromosome 17 p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6: 413-21, 1991.
14. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M, p53 mutations and histological type of invasive breast carcinoma. Cancer Res 53: 4665-9, 1993.
15. Reich NC, Levine AJ: Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature 308: 199-201, 1984.
16. Rogel A, Popliker M, Webb CG, Oren M: p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5: 2851-5, 1985.
17. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-9, 1990.
18. Clark GM and McGuire WL: Follow-up study of HER -2/neu amplification in primary breast cancer. Cancer Res 51: 944-8, 1991.
19. Paterson MC, Dietrich KD, Danyluk J, Paterson AHG, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, and Fourney RM: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 52: 556-7, 1991.
20. Donovan-Peluso M, Contento AM, Toban H, Ripepi B, and Locker J: Oncogene amplification in breast cancer. Am J Pathol 138: 835-45, 1991.
21. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA and Freister HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Research 2: 2597-602, 1992.
22. Barnes MD, Dublin EA, Fisher CJ, levison DA and Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469-76, 1993.
23. Elledge RM, Fuqua SAW, Clark GM, Pujol P and Allred DC: The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res. Treat 27: 95-102, 1993.
24. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchagen DL, Nau MM, Gazder AF and Linnoila RI: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7: 743-9, 1992.
25. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Eltson CW, Blarney RW and Ellis IO: p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression. and estrogen receptor. Br J Cancer 66: 583-8,1992.
26. Eyfjörd JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM and Anamthawat-Jonsson K: p53 Abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55: 646-51, 1995.